GO
Loading...

Drugmaker Schwarz Pharma Gets Nod for Parkinson's Drug

Drug maker Schwarz Pharma said Tuesday that its Neupro treatment for Parkinson's disease has received approval in Europe to treat the illness in its advanced stages.

The drug was first approved in March 2006 in Europe to treat early stages of the illness in March 2006 and is available in Germany, Austria, Switzerland, Britain, Ireland, Denmark, Norway, Sweden, Greece and Spain.

The company, which is set to become part of Belgium's UCB in a 4.4 billion euro ($5.7 billion) deal, has said that sales of the drug could reach as much as 350 million euros annually.

Shares of Schwarz Pharma were up more than half a percent to 106.13 euros in Frankfurt trading.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video

  • Discussing the valuation and skepticism surrounding Chinese smartphone maker Xiaomi, with CNBC's Jon Fortt; Slava Rubin, Indiegogo; and Jon Fortt of Daily Mail North America.

  • Discussing the issue of cyberwarfare and Sony's next move for "The Interview," with Slava Rubin, Indiegogo; John Steinberg, Daily Mail North America; and CNBC's Jon Fortt.

  • Low volatility and poor small cap performance have made it hard for active managers to yield returns, but a reversal is in store, says Fundstrat founder Tom Lee.